AbCellera Biologics Inc.

AbCellera Biologics Inc. is a clinical-stage biotechnology company that discovers and develops antibody-based medicines targeting unmet medical needs in endocrinology, women's health, immunology, and oncology. It employs an advanced antibody discovery platform that searches, decodes, and analyzes natural immune systems to identify therapeutic antibodies for preventing and treating diseases. Key internal programs include ABCL635, a non-hormonal medicine in Phase 2 clinical trials for moderate-to-severe vasomotor symptoms, and ABCL575, a fully human, half-life extended monoclonal antibody in Phase 1 trials for T-cell-mediated autoimmune conditions like atopic dermatitis. The company maintains strategic research collaborations and license agreements with leading pharmaceutical firms such as Eli Lilly and Company, AbbVie Inc., and Biogen Inc., facilitating milestone payments and royalties. AbCellera Biologics Inc. also advances preclinical candidates in metabolic, endocrine, and oncology areas, including T-cell engagers. Founded in 2012 and headquartered in Vancouver, Canada, it plays a vital role in accelerating antibody therapeutics through proprietary technologies like microfluidic cell culture.